Vaccines

<a href="https://www.bioagilytix.com/blog/category/neoantigens/">Neoantigens</a>

Neoantigens Revive Vaccine Opportunities in Immuno-Oncology

  • November 18, 2022

Neoantigens are novel proteins that form on cancer cells following the development of mutations in the tumor-cell DNA. These proteins are new to the immune…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cdc-assay/">CDC Assay</a>

ADCC and CDC Assay: Validation and Optimization

  • July 18, 2022

Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on the surface of a cell, targeting…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/vaccines/">Vaccines</a>

The Broad Array of Vaccine Options for COVID-19

  • May 4, 2022

As we pass the two-year anniversary of the start of the coronavirus pandemic, we are reminded of where we started and how far we have…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/industry-update/">Industry Update</a>

The Benefits of Hiring the Right CRO

  • January 27, 2021

Short for Contract Research Organization, a CRO is a company that provides clinical research support to the pharmaceutical, biotech and medical industries on a contract…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Answering Your Questions on Developing a Relative Potency Assay for an Anti-Influenza mAb

  • May 22, 2020

Dr. Jeff Patrick answers questions on how BioAgilytix translated a diagnostic virus neutralization method to a quantitative relative potency assay for an anti-viral antibody.

Find Out More